enGene (ENGN) Competitors $8.80 -0.01 (-0.11%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$8.48 -0.32 (-3.58%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. HROW, HRMY, SDGR, PAHC, RCUS, AUPH, STOK, SNDX, EVO, and ORICShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Harrow (HROW), Harmony Biosciences (HRMY), Schrodinger (SDGR), Phibro Animal Health (PAHC), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), Stoke Therapeutics (STOK), Syndax Pharmaceuticals (SNDX), Evotec (EVO), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors Harrow Harmony Biosciences Schrodinger Phibro Animal Health Arcus Biosciences Aurinia Pharmaceuticals Stoke Therapeutics Syndax Pharmaceuticals Evotec Oric Pharmaceuticals Harrow (NASDAQ:HROW) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Is HROW or ENGN more profitable? enGene has a net margin of 0.00% compared to Harrow's net margin of -4.49%. Harrow's return on equity of -2.18% beat enGene's return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.18% -0.35% enGene N/A -39.86%-34.15% Which has more volatility and risk, HROW or ENGN? Harrow has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Do institutionals and insiders have more ownership in HROW or ENGN? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 15.2% of Harrow shares are owned by company insiders. Comparatively, 10.4% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, HROW or ENGN? Harrow has higher revenue and earnings than enGene. Harrow is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$227.66M6.41-$17.48M-$0.25-157.76enGeneN/AN/A-$55.14M-$1.90-4.63 Do analysts prefer HROW or ENGN? Harrow currently has a consensus price target of $68.50, indicating a potential upside of 73.68%. enGene has a consensus price target of $19.50, indicating a potential upside of 121.59%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Harrow.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67enGene 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media favor HROW or ENGN? In the previous week, enGene had 4 more articles in the media than Harrow. MarketBeat recorded 10 mentions for enGene and 6 mentions for Harrow. Harrow's average media sentiment score of 1.07 beat enGene's score of 0.27 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryHarrow beats enGene on 10 of the 16 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$451.00M$3.37B$6.12B$10.45BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-4.6322.7785.3827.36Price / SalesN/A491.80602.69196.46Price / CashN/A46.7037.4661.86Price / Book1.6410.5512.516.81Net Income-$55.14M-$52.58M$3.32B$276.80M7 Day Performance-1.01%0.09%0.60%0.42%1 Month Performance44.98%15.61%10.53%7.86%1 Year Performance2.56%15.13%74.30%41.24% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene2.9064 of 5 stars$8.80-0.1%$19.50+121.6%+4.8%$451.00MN/A-4.6331Analyst ForecastHROWHarrow2.9586 of 5 stars$42.19+0.1%$68.50+62.4%-26.3%$1.56B$227.66M-168.97180HRMYHarmony Biosciences4.7068 of 5 stars$27.14+2.1%$45.50+67.6%-25.0%$1.56B$772.53M8.75200Analyst ForecastSDGRSchrodinger2.6295 of 5 stars$20.89-1.9%$26.57+27.2%+16.8%$1.54B$237.92M-8.42790Analyst ForecastGap UpPAHCPhibro Animal Health4.2984 of 5 stars$37.83+0.1%$28.40-24.9%+62.1%$1.53B$1.30B31.922,475Analyst ForecastRCUSArcus Biosciences1.9913 of 5 stars$14.01-3.2%$23.38+66.8%-5.2%$1.49B$262M-4.42500Analyst ForecastAUPHAurinia Pharmaceuticals3.0058 of 5 stars$11.16-1.4%$13.00+16.4%+59.3%$1.47B$235.13M26.01300STOKStoke Therapeutics3.0271 of 5 stars$26.24-2.1%$25.57-2.6%+180.5%$1.44B$199.89M30.86100Analyst ForecastSNDXSyndax Pharmaceuticals3.656 of 5 stars$16.47+0.4%$39.22+138.1%-23.8%$1.41B$23.68M-4.22110EVOEvotec2.0051 of 5 stars$3.97-0.4%$7.00+76.1%+35.5%$1.41B$777.33M0.004,827ORICOric Pharmaceuticals4.2736 of 5 stars$14.40-0.1%$17.29+20.0%+46.0%$1.40BN/A-7.6280Gap Up Related Companies and Tools Related Companies HROW Competitors HRMY Competitors SDGR Competitors PAHC Competitors RCUS Competitors AUPH Competitors STOK Competitors SNDX Competitors EVO Competitors ORIC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
